LMRI

Rating buyAI Memo

Lumexa Imaging

As of 2026-06-27/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-06-27 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

6‑12m

Key catalyst

Next quarterly read on cash conversion and leverage • 2026-09-30

Expected move: +22%

Biggest risk

The main pushback is balance-sheet and reimbursement sensitivity. Q1 still carried about $842.0 million of debt obligations, de novo expansion remains capital intensive, and reimbursement/collections are important because payor terms drive realized pricing [#10-Q-2026-05-12]. A good operating story can still disappoint if cash conversion or center ramp timing slips.

Invalidation

Break below $9 or thesis failure.

What would change my mind?

Primary-source evidence supports a credible growth algorithm: Q1 revenue rose 3.1%, adjusted EBITDA was $51.2 million, same-center advanced volume growth was 5.6%, and full-year 2026 guidance was reiterated [#SEC-8K-2026-05-12]. The March 2026 results also pointed to margin support from advanced imaging mix, de novo ramp, and leverage reduction [#SEC-8K-2026-03-26].

Research note

Recommendation

buy

Confidence

medium

As of

2026-06-27

Base target

$15

p=45%

Bull target

$17

p=35%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

2026 same-center advanced imaging growth holds above total procedure growth
Center-addition pipeline converts into volume growth
Primary-source evidence supports a credible growth algorithm: Q1 revenue rose 3.1%, adjusted EBITDA was $51.2 million, same-center advanced volume growth was 5.6%, and full-year 2026 guidance was reiterated [#SEC-8K-2026-05-12].

BearKey bullets

Accounts receivable quality needs monitoring because attorney-liens receivables were 36% of receivables and can take more than 36 months to resolve [#10-Q-2026-05-12].
Growth execution depends on de novo openings, tuck-in integration, equipment spending, and local demand ramp; misses here would pressure the current 2026 guide [#SEC-8K-2026-05-12] [#10-Q-2026-05-12].
Leverage remains material, with total debt obligations around $842.0 million at March 31, 2026, even though the company was in covenant compliance [#10-Q-2026-05-12].

WatchKey bullets

Next quarterly read on cash conversion and leverage

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $15 (p=45%)

Bull/Bear spread: +43% / -26%

Vs latest close: Bull +43% · Base +22% · Bear -26%

Scenario probabilities

Bull Target: $17 (p=35%)Base Target: $15 (p=45%)Bear Target: $9 (p=20%)

Commentary

News flow over the last 30-45 days has been mostly earnings-driven and constructive, centered on the May 12, 2026 Q1 release and transcript coverage. Primary-source support is strong for the operating update, but external revision data and target-count depth are thin, so this still reads more like a constructive monitoring name than a fully validated consensus long. The deterministic prior improved versus the older baseline, but confidence should stay moderate because the market still needs proof on deleveraging and center-ramp execution.

As of 2026-06-27 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

2026 same-center advanced imaging growth holds above total procedure growth
Center-addition pipeline converts into volume growth

Scenarios

Bull Target (Scenario probability)

$17 / p=35% prob

Base Target (Scenario probability)

$15 / p=45% prob

Bear Target (Scenario probability)

$9 / p=20% prob

Price $12 as of 2026-06-26

Nearest Scenario: Base (∆ 22%)

Targets vs latest close: Bull +43% · Base +22% · Bear -26%

Sentiment & Exposure

News Sentiment (30d)

0.35

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-30
Next quarterly read on cash conversion and leverage
The Q1 2026 filing showed cash of $51.2 million, total debt obligations of about $842.0 million, and compliance with credit covenants, so the next reporting cycle matters for proving that earnings growth is translating into cash generation and incremental deleveraging rather than just volume growth [#10-Q-2026-05-12] [#SEC-8K-2026-03-26].
Prob 58.00% • Move 14.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

2026 same-center advanced imaging growth holds above total procedure growth
2026-12-31
Q1 2026 showed consolidated advanced procedures up 6.8%, system-wide advanced procedures up 6.9%, and same-center advanced volume growth of 5.6%, while full-year 2026 guidance was reiterated. If advanced modality mix stays favorable, the setup supports revenue and EBITDA realization through the rest of 2026 [#SEC-8K-2026-05-12].
Prob 68% • Move 18% • Priced-in 45%
Center-addition pipeline converts into volume growth
2026-12-31
Management announced four additional centers in May 2026, including two tuck-in acquisitions and two de novos, and said it remained on track for 8-10 de novos in 2026. Execution on openings and ramps is a concrete operating lever for scan growth and local density [#SEC-8K-2026-05-12].
Prob 62% • Move 16% • Priced-in 35%

Risks

Accounts receivable quality needs monitoring because attorney-liens receivables were 36% of receivables and can take more than 36 months to resolve [#10-Q-2026-05-12].
Growth execution depends on de novo openings, tuck-in integration, equipment spending, and local demand ramp; misses here would pressure the current 2026 guide [#SEC-8K-2026-05-12] [#10-Q-2026-05-12].
Leverage remains material, with total debt obligations around $842.0 million at March 31, 2026, even though the company was in covenant compliance [#10-Q-2026-05-12].
Reimbursement and collections matter because pricing depends on Medicare, Medicaid, managed-care, and commercial contracts; the 10-Q explicitly flags reimbursement-rate pressure as a business risk [#10-Q-2026-05-12].

Peers

Symbol	Summary
IRMD	Closest size-matched health care equipment/services comparator in the packet, but still not a direct outpatient imaging operator; useful mainly as a small-cap medtech sentiment check.
AVNS	Another size-matched sector comp rather than a direct operating peer; helps frame whether LMRI's valuation discount reflects company-specific execution risk versus broader medtech pressures.
AORT	Rough market-cap peer inside health care equipment/services, but business overlap is limited; peer read-through should stay cautious.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-06-27

AI Stock Memo: LMRI - Lumexa Imaging - RankAlpha